For patients with small cell lung cancer, chest radiotherapy increases survival, decreases recurrence
the ONA take:
According to a new study published in The Lancet, patients with advanced small cell lung cancer (SCLC) experienced prolonged survival and reduced recurrence of the disease after being treated prophylactic cranial radiotherapy plus thoracic radiotherapy compared with those treated with prophylactic cranial radiotherapy alone.
In the phase 3 clinical study, researchers enrolled 498 adults with advanced SCLC who had already responded to first-line chemotherapy from 42 hospitals in Europe. Patients were randomized to receive either prophylactic cranial radiotherapy plus chest radiotherapy or prophylactic cranial radiotherapy alone. Radiation was administered over 2 weeks and patients were followed for an average of 2 years.
The researchers found that patients survival rates were similar between both groups after 1 year, but they found that after 2 years, 13% of patients treated with combination radiotherapy were alive, while only 3% of those treated with prophylactic cranial radiotherapy were alive. In addition, 20% those who received combination radiotherapy experienced recurrence in the thoracic region compared with 46% of the cranial radiotherapy group.
The authors suggest that chest radiation therapy should be considered as a treatment approach in patients with extensive small cell lung cancer who have responded to first-line chemotherapy.
SCLC patients experienced prolonged survivalafter being treated prophylactic cranial radiotherapy.
For patients with advanced small cell lung cancer, thoracic radiotherapy alongside standard treatment may boost long-term survival and reduce the likelihood of cancer recurrence in the chest, according to researchers.
Small cell lung cancer (SCLC) accounts for around 10-15% of all lung cancer cases. It is almost always caused by smoking and tends to spread rapidly to other parts of the body, meaning it is often diagnosed in its advanced stages.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|